Martha Shuping, MD
Psychiatry · Winston Salem, NCNPI 1245245737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,110 of the $66,732 with a category attached, or 93.1%. AbbVie accounts for 98.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $28,214 and has fallen 82.8% since, to $4,846 in 2024. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $311.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Teva Pharmaceuticals USA, Inc.$345
- Sunovion Pharmaceuticals Inc.$313
- Axsome Therapeutics, Inc.$129
- Johnson & Johnson$110
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
- plus $264 from 4 others
What the payments were for
- Speaking & faculty fees$62,11093%
- Travel & lodging$1,5662%
- Food & beverage$2,9774%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $65,473 |
| Teva Pharmaceuticals USA, Inc. | 15 | $345 |
| Sunovion Pharmaceuticals Inc. | 7 | $313 |
| Axsome Therapeutics, Inc. | 4 | $129 |
| Johnson & Johnson | 1 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $97 |
| Neurocrine Biosciences, Inc. | 1 | $90 |
| Alkermes, Inc. | 1 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,732 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 142 | $221,566 |
| CaplytaLumateperone Tosylate | 38 | $60,832 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $24,616 |
| UbrelvyUbrogepant | 12 | $18,851 |
| TrintellixVortioxetine Hydrobromide | 15 | $17,687 |
| FanaptIloperidone | 16 | $17,005 |
| BelsomraSuvorexant | 14 | $5,856 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 132 | $4,760 |
| Quetiapine Fumarate | 112 | $3,465 |
| Alprazolam | 357 | $3,378 |
| Clonazepam | 230 | $2,680 |
| Paliperidone ErPaliperidone | 20 | $2,443 |
| Gabapentin | 155 | $2,321 |
| Methylphenidate Hcl | 42 | $2,231 |
| Vilazodone Hcl | 20 | $1,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy | $65,473 | $240,417154 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $97 | $60,83238 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $34 | $17,00516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Winston Salem
- Brian FarahWinston Salem$605K
- Ruth BencaWinston Salem$114K
- Richard JacksonWinston Salem$92K
- Adam McDonoughWinston Salem$69K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.